Recombinant DNA Technology Market Research Report - Forecast to 2027

Recombinant DNA Technology Market Research Report: By Product (Medical, Non-Medical), Component (Expression System, Cloning Vector), Application (Food & Agriculture, Health & Disease), End-User (Biotechnology Companies, Pharmaceuticals) – Forecast to 2027

ID: MRFR/LS/4389-HCR | February 2021 | Region: Global | 100 pages

Recombinant DNA Technology Market Overview


The Recombinant DNA Technology Market is predicted to grow market approximately 6.9% of CAGR for the forecast period of 2017 to 2023. The process that can alter and manipulate the DNA sequences is known as recombinant DNA technology. Recombinant DNA technology is used in genetically modified organisms and products with specific or superior abilities to survive in harsh conditions (G.M. crops), high productivity, and resistance to certain chemicals. 


Recombinant DNA technology has a huge application in many sectors. But the practical application of biotechnology in the specific field of genomics, development of pharmaceutical therapeutics, applied immunology, and diagnostic tools are the dominating factor for the Recombinant DNA Technology Market Growth. In the creation of recombinant DNA, many biological methods are involved by the research and development market. Moreover, the Recombinant DNA Technology treatment was developed to treat the leukemia disorder in conjugation between the University of Pennsylvania and the Novartis Corp. 


According to the Recombinant DNA Technology Market Outlook report, the global market is segmented into application, components, products, and end-users, fueling the Market Size for the research period. Along with that, the intended audiences such as Recombinant DNA Technology Test Kit Suppliers, Medical Research Laboratories, Research and Development (R&D) Companies, Recombinant DNA Technology Test Kit Manufacturers, and Academic Medical Institutes and Universities are playing an important role in increasing the demand of the global market for the forecast period. 


COVID-19 Impact Analysis


The ongoing COVID-19 pandemic has affected the Disposable Incontinence Products (DIPs) industry, potential opportunities, and market trends. During the pandemic, the global market lost its productivity and sales as many regions were in lockdown. But after a certain time, the government has permitted the essential items to be sold, which has brought little opportunities for the global market.


According to the Recombinant DNA Technology Market Forecast report, the global key players have adopted various methods and strategies to deliver the product to their customers.


Market Overview 



  • Major Drivers of the Market


The global Recombinant DNA Technology Market is driving its growth due to major factors such as the growing adoption of genetically modified biopesticides and crops and the increasing adoption of recombinant DNA technology in the industry biopharmaceuticals and the growing burden of chronic diseases. Moreover, the effective therapeutics demand for disease treatment is increasing due to a robust biopharmaceuticals pipeline and the growing requirements to enhance the recombinant protein production capacity.


The U.S. Food and Drug Administration (FDA) had approved more recombinant drugs as the pharmaceutical products synthesized through recombinant DNA technology. This approval has generated a secure feeling among the population, and the demand for recombinant DNA technology has been increased among the Recombinant DNA Technology Market industries.



  • Opportunities of the global market


I the North American and Western European regions, the genetic testing market grows larger, spreading its hands to many remote areas. 


Therefore, this can bring more opportunities for the service providers and companies to make the tests more affordable. Along with that, the global Recombinant DNA Technology Market is trying to enter the untapped regions to bring lucrative opportunities. 



  • Market Restraints


The global Recombinant DNA Technology Market might face major restraints due to the risk associated with gene therapy. Another major restraint can be the stringent regulation for the approval of the product in various regions.


Therefore, the global key players are focusing on these issues to get a better outcome. 



  • Market Growth challenges


The global Recombinant DNA Technology Market might face major challenges due to the potential risk occurring from the Gene therapy.


Moreover, the risks associated with the operations might bring challenges to the global Market. Hence, the key players are working on these factors to get the proper solution to these challenges. 



  • Cumulative growth Analysis


Presently, the Recombinant DNA Technology Market Size has improved compared to the previous years, which predicts that the global market has the higher Market Value for the forecast period. 


Moreover, various regions such as America, Europe, the Middle East, Africa, and the Asia Pacific have been accounted to generate the higher Market Value in the upcoming years.


Market Segment Overview


By Product: The Recombinant DNA Technology Market has been classified into non-medical, medical, and others based on the product segment. 


Further, the non-medical segment is sub-classified into specialty chemicals, biotech crops, and others. On the other hand, the medical segment is sub-classified into human proteins, therapeutic agents, and vaccines. 



  • By Components:


The global Recombinant DNA Technology Market has been divided into a cloning vector, expression system, and component segment. 


Further, the Market Outlook report has mentioned that the cloning vector segment is sub-divided into cosmid, plasmid, phage, Human Artificial Chromosome (HAC), Yeast Artificial Chromosome (YAC), and Bacterial Artificial Chromosome (BAC). On the other hand, the expression system segment is sub-divided into bacteria, mammalian, baculovirus or insect, yeast, and others.



  • By Applications:


The global Recombinant DNA Technology Market has been classified into health and disease, food and agriculture, environment, and others based on the application segment.


Among these, the health & disease segment is generating the highest Market Share in the forecast period due to the increasing chronic diseases and wide range of recombinant products presence for the treatment of human disease like vaccines, drugs, etc.



  • By End-users:


The end-user segment of the global Recombinant DNA Technology Market has been divided into pharmaceuticals, academic and government research institutes, biotechnology companies, and others.


The biotechnology and pharmaceuticals companies are generating the higher Market Share for the research period due to their drug development capabilities. 


Figure 1: - Global Recombinant DNA Technology Market Share, by Region


 Recombinant DNA Technology Market Share


Regional Analysis


The global Recombinant DNA Technology Market has been segmented into Europe, the Americas, the Middle East and Africa, and the Asia Pacific based on regional segments. 


Among all, the Americas Market has accounted for the higher major share for the research period due to the widespread applications of this technique in genetically modified crops' development, veterinary products' development, gene therapy, and the production of biopesticides' and biofuels' production. Hence, these factors are fueling the Market Growth during the forecast period. Moreover, the European region holds the second dominating marketing region that contributes the largest Market share in the assessment period due to the government's increasing investments and hospital facilities for quality healthcare facilities. Also, the market is growing with the low cost of sequencing, increasing collaborations and partnerships, and the increasing demands of the research laboratories for the NGS procedure. 


Competitive Landscape Analysis


The global Recombinant DNA Technology Market Trends with the collective efforts of the key players in various regions of the world. These key players are:



  • Amgen Inc. (U.S.), 

  • F. Hoffmann-La Roche Ltd (Switzerland), 

  • Profacgen (U.S.), 

  • Novartis AG (Switzerland), 

  • Novo Nordisk A/S (Denmark), 

  • Genscript Biotech (U.S.), 

  • Pfizer Inc. (U.S.), 

  • Sanofi S.A. (France), 

  • Eli Lilly and Company (U.S.), 

  • Biogen Inc. (U.S.), 

  • Biocon Limited (India), 

  • Boehringer Ingelheim (Germany), 

  • Merck & Co., Inc. (U.S.), 

  • Cibus (U.S.), 

  • GlaxoSmithKline plc (UK), 

  • New England Biolabs (U.S.), 

  • Horizon Discovery Group PLC (U.S.),

  • Monsanto Company (U.S.).


The above-mentioned key players have lucrative opportunities due to the large application of the Recombinant DNA Technology Market Trends.


Recent Developments



  • Clustered regularly interspaced short palindromic repeats (CRISPR) is a recent development that has brought solutions to the different species' problems. It has been developed to target the destruction of genes in human body cells.


Report Overview


The Recombinant DNA Technology Market Analysis report has involved both primary research and secondary research to get the insight data of the global market. In the primary research, primary quantitative surveys have been conducted to get the views of the wholesalers, manufacturers, and retailers. Moreover, the secondary research has gathered data about the competitive landscape, company development, market access scenario, epidemiology study, and market dynamics. Along with that, the data analysis has involved event analysis, market size estimation, company share analysis, market factor analysis, trade analysis, cost analysis, trend analysis, and others in measuring the performance of the global market.


Further, the Recombinant DNA Technology Market Analysis report has highlighted the recent developments over various world regions. Though, the report has mentioned some specific strategies and methods used by the key players to enhance the growth of the Market.


Segmental Table:


By Product:



  • non-medical, 

  • medical,

  • others


By Components: 



  • cloning vector, 

  • expression system, 

  • others


By Application:



  • health and disease, 

  • food and agriculture, 

  • environment, 

  • others


By End-users:



  • pharmaceuticals, 

  • academic and government research institutes, 

  • biotechnology companies, 

  • others



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Recombinant DNA technology is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism.

Recombinant DNA Technology Market is expected to exhibit a strong 6.9% CAGR over the forecast period from 2017 to 2023.

Growing demand for recombinant DNA technology in therapeutic applications is a major driver for the market.

Americas hold the dominant share in the global Recombinant DNA Technology Market.

Leading players in the Recombinant DNA Technology Market include Novartis, Profacgen, and Amgen, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Recombinant DNA Technology Market, by Product

6.1 Introduction

6.2 Medical

6.2.1 Market Estimates & Forecast, 2020-2027

6.2.2 Therapeutic Agent

6.2.2.1 Market Estimates & Forecast, 2020-2027

6.2.3 Human Protein

6.2.3.1 Market Estimates & Forecast, 2020-2027

6.2.4 Vaccine

6.2.4.1 Market Estimates & Forecast, 2020-2027

6.3 Non-Medical

6.3.1 Market Estimates & Forecast, 2020-2027

6.3.2 Biotech Crops

6.3.2.1 Market Estimates & Forecast, 2020-2027

6.3.3 Specialty Chemicals

6.3.3.1 Market Estimates & Forecast, 2020-2027

6.3.4 Others

6.3.4.1 Market Estimates & Forecast, 2020-2027

6.4 Others

Chapter 7. Global Recombinant DNA Technology Market, by Component

7.1 Introduction

7.2 Expression System

7.2.1 Market Estimates & Forecast, 2020-2027

7.2.2 Mammalian

7.2.2.1 Market Estimates & Forecast, 2020-2027

7.2.3 Bacteria

7.2.3.1 Market Estimates & Forecast, 2020-2027

7.2.4 Yeast

7.2.4.1 Market Estimates & Forecast, 2020-2027

7.2.4 BaculovirU.S./Insect

7.2.4.1 Market Estimates & Forecast, 2020-2027

7.2.5 Others

7.2.5.1 Market Estimates & Forecast, 2020-2027

7.3 Cloning Vector

7.3.1 Market Estimates & Forecast, 2020-2027

7.3.2 Plasmid

7.3.2.1 Market Estimates & Forecast, 2020-2027

7.3.3 Phage

7.3.3.1 Market Estimates & Forecast, 2020-2027

7.3.4 Cosmid

7.3.4.1 Market Estimates & Forecast, 2020-2027

7.3.5 Bacterial Artificial Chromosome (BAC)

7.3.5.1 Market Estimates & Forecast, 2020-2027

7.3.6 Yeast Artificial Chromosome (YAC)

7.3.6.1 Market Estimates & Forecast, 2020-2027

7.3.7 Human Artificial Chromosome (HAC).

7.3.7.1 Market Estimates & Forecast, 2020-2027

7.4 Others

Chapter 8. Global Recombinant DNA Technology Market, by Application

8.1 Introduction

8.2 Food & Agriculture

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Health & Disease

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Environment

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Others

Chapter 9. Global Recombinant DNA Technology Market, by End-U.S.er

9.1 Introduction

9.2 Biotechnology Companies

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Academic & Government Research Institutes

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Pharmaceuticals

9.4.1 Market Estimates & Forecast, 2020-2027

9.5 Others

Chapter .8 Global Recombinant DNA Technology Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 U.S.

8.2.1.1 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 U.K.

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 Republic of Korea

8.4.6 Rest of Asia Pacific

8.5 The Middle East & Africa

8.5.1 United Arab Emirates

8.5.2 Saudi Arabia

8.5.3 Oman

8.5.4 Kuwait

8.5.5 Qatar

8.5.6 Rest of the Middle East & Africa

Chapter 9 Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

9.3.1 Key Developments

Chapter 10 Company Profiles

10.1 F. Hoffmann-La Roche Ltd

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials

10.1.4 SWOT Analysis

10.2 Profacgen

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Amgen Inc.

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Novartis AG

10.4.1 Company Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Genscript Biotech

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.6 Pfizer Inc.

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.7 Novo Nordisk A/S

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Eli Lilly and Company

10.8.1 Company Overview

10.8.2 Product/Business Segment Overview

10.8.3 Financial Overview

10.8.4 Key Development

10.8.5 SWOT Analysis

10.9 Sanofi S.A.

10.9.1 Company Overview

10.9.2 Product Overview

10.9.3 Financial overview

10.9.4 Key Developments

10.10 Merck & Co., Inc.

10.10.1 Company Overview

10.10.2 Product Overview

10.10.3 Financial overview

10.10.4 Key Developments

10.11 Biogen Inc.

10.11.1 Company Overview

10.11.2 Product Overview

10.11.3 Financial overview

10.11.4 Key Developments

10.12 Others

Chapter 17 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s View Point

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Prediction of the Pharmaceutical Industry

Chapter 12 Appendix

LIST OF TABLES

Table 1 Recombinant DNA technology Industry Synopsis, 2020-2027

Table 2 Recombinant DNA Technology Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Recombinant DNA Technology Market, by Region, 2020-2027, (USD Million)

Table 4 Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 5 Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 6 Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 7 Recombinant DNA Technology Market, by End-U.S.er, 2020-2027, (USD Million)

Table 8 North America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 9 North America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 10 North America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 11 North America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 12 U.S. Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 13 U.S. Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 14 U.S. Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 15 U.S. Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 16 Canada Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 17 Canada Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 18 Canada Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 19 Canada Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 20 South America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 21 South America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 22 South America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 23 South America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 24 Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 25 Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 26 Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 27 Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 28 Western Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 29 Western Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 30 Western Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 31 Western Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 32 Eastern Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 33 Eastern Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 34 Eastern Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 35 Eastern Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 36 Asia Pacific Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 37 Asia Pacific Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 38 Asia Pacific Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 39 Asia Pacific Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 40 The Middle East & Africa Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 41 The Middle East & Africa Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 42 The Middle East & Africa Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 43 The Middle East & Africa Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation of the Recombinant DNA Technology Market

Figure 3 Segmentation Market Dynamics for the Recombinant DNA Technology Market

Figure 4 Global Recombinant DNA Technology Market Share, by Product 2020

Figure 5 Global Recombinant DNA Technology Market Share, by Component 2020

Figure 6 Global Recombinant DNA Technology Market Share, by Application 2020

Figure 7 Global Recombinant DNA Technology Market Share, by End-User2020

Figure 8 Global Recombinant DNA Technology Market Share, by Region, 2020

Figure 9 Americas Recombinant DNA Technology Market Share, by Country, 2020

Figure 10 Europe Recombinant DNA Technology Market Share, by Country, 2020

Figure 11 Asia Pacific Recombinant DNA Technology Market Share, by Country, 2020

Figure 12 Middle East & Africa Recombinant DNA Technology Market Share, by Country, 2020

Figure 13 Global Recombinant DNA Technology Market: Company Share Analysis, 2020 (%)

Figure 14 F. Hoffmann-La Roche Ltd: Key Financials

Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 17 Profacgen: Key Financials

Figure 18 Profacgen: Segmental Revenue

Figure 19 Profacgen: Geographical Revenue

Figure 20 Amgen Inc.: Key Financials

Figure 21 Amgen Inc.: Segmental Revenue

Figure 22 Amgen Inc.: Geographical Revenue

Figure 23 Novartis AG: Key Financials

Figure 24 Novartis AG: Segmental Revenue

Figure 25 Novartis AG: Geographical Revenue

Figure 26 Genscript Biotech: Key Financials

Figure 27 Genscript Biotech: Segmental Revenue

Figure 28 Genscript Biotech: Geographical Revenue

Figure 29 Pfizer Inc.: Key Financials

Figure 30 Pfizer Inc.: Segmental Revenue

Figure 31 Pfizer Inc.: Geographical Revenue

Figure 32 Novo Nordisk A/S: Key Financials

Figure 33 Novo Nordisk A/S: Segmental Revenue

Figure 34 Novo Nordisk A/S: Geographical Revenue

Figure 35 Eli Lilly and Company: Key Financials

Figure 36 Eli Lilly and Company: Segmental Revenue

Figure 37 Eli Lilly and Company: Geographical Revenue